 | • レポートコード：MRC22iR11003 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、237ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品 |
| Single User | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Five User | ￥880,452 (USD5,949) | ▷ お問い合わせ |
| Enterprise License | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に137.1億ドルであった世界の白血病治療薬市場規模が、2022年に146.4億ドルになり、2027年まで年平均6.92%で成長して204.9億ドルに達すると予測しています。本レポートでは、白血病治療薬の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場洞察、種類別（急性リンパ性白血病、急性骨髄性白血病、慢性リンパ性白血病、慢性骨髄性白血病）分析、治療法別（化学療法、標的薬＆免疫療法）分析、分子種類別（バイオロジクス、低分子化合物）分析、投与方法（注射、経口）分析、地域別（南北アメリカ、アジア太平洋、ヨーロッパ）分析、競争状況、企業情報などの項目を掲載しています。本書ではAbbVie Inc.、AstraZeneca PLC、Biogen Inc、Bristol Myers Squibb Company、Eisai Co., Ltd、F. Hoffmann-La Roche AG、Gilead Sciences, Inc.、GlaxoSmithKline PLC、Incyte Corp、Johnson & Johnson Services, Inc.、Merck KGaA、Novartis International AG、Pfizer Inc.、Sanofi S.A.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場洞察 ・世界の白血病治療薬市場規模：種類別 - 急性リンパ性白血病の市場規模 - 急性骨髄性白血病の市場規模 - 慢性リンパ性白血病の市場規模 - 慢性骨髄性白血病の市場規模 ・世界の白血病治療薬市場規模：治療法別 - 化学療法の市場規模 - 標的薬＆免疫療法の市場規模 ・世界の白血病治療薬市場規模：分子種類別 - バイオロジクスの市場規模 - 低分子化合物の市場規模 ・世界の白血病治療薬市場規模：投与方法別 - 注射剤の市場規模 - 経口剤の市場規模 ・世界の白血病治療薬市場規模：地域別 - 南北アメリカの白血病治療薬市場規模 - アジア太平洋の白血病治療薬市場規模 - ヨーロッパの白血病治療薬市場規模 ・競争状況 ・企業情報 |
The Global Leukemia Therapeutics Market size was estimated at USD 13.71 billion in 2021 and expected to reach USD 14.64 billion in 2022, and is projected to grow at a CAGR 6.92% to reach USD 20.49 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Leukemia Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myeloid Leukemia.
Based on Treatment Type, the market was studied across Chemotherapy and Targeted Drugs & Immunotherapy.
Based on Molecule Type, the market was studied across Biologics and Small Molecules.
Based on Mode of Administration, the market was studied across Injectable Mode and Oral Mode.
Based on Gender, the market was studied across Female and Male.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Leukemia Therapeutics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Leukemia Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Leukemia Therapeutics Market, including AbbVie Inc., AstraZeneca PLC, Biogen Inc, Bristol Myers Squibb Company, Eisai Co., Ltd, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corp, Johnson & Johnson Services, Inc., Merck KGaA, Novartis International AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Leukemia Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Leukemia Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Leukemia Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Leukemia Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Leukemia Therapeutics Market?
6. What is the market share of the leading vendors in the Global Leukemia Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Leukemia Therapeutics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of leukemia cases
5.1.1.2. Growing need for cancer therapy
5.1.1.3. Increasing investment in healthcare sector and developmental therapeutics for acute lymphoblastic leukemia
5.1.2. Restraints
5.1.2.1. High cost of treatment and development of new therapeutics
5.1.3. Opportunities
5.1.3.1. Development of innovative diagnostic and therapeutics for leukemia patients
5.1.3.2. Expanding investments in the healthcare sector and favorable government initiatives
5.1.4. Challenges
5.1.4.1. Stringent regulatory scenario
5.2. Cumulative Impact of COVID-19
6. Leukemia Therapeutics Market, by Type
6.1. Introduction
6.2. Acute Lymphocytic Leukemia
6.3. Acute Myeloid Leukemia
6.4. Chronic Lymphocytic Leukemia
6.5. Chronic Myeloid Leukemia
7. Leukemia Therapeutics Market, by Treatment Type
7.1. Introduction
7.2. Chemotherapy
7.3. Targeted Drugs & Immunotherapy
8. Leukemia Therapeutics Market, by Molecule Type
8.1. Introduction
8.2. Biologics
8.3. Small Molecules
9. Leukemia Therapeutics Market, by Mode of Administration
9.1. Introduction
9.2. Injectable Mode
9.3. Oral Mode
10. Leukemia Therapeutics Market, by Gender
10.1. Introduction
10.2. Female
10.3. Male
11. Americas Leukemia Therapeutics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Leukemia Therapeutics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Leukemia Therapeutics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. AbbVie Inc.
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. AstraZeneca PLC
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Biogen Inc
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Bristol Myers Squibb Company
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Eisai Co., Ltd
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. F. Hoffmann-La Roche AG
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Gilead Sciences, Inc.
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. GlaxoSmithKline PLC
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Incyte Corp
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Johnson & Johnson Services, Inc.
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Merck KGaA
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Novartis International AG
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Pfizer Inc.
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Sanofi S.A.
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Takeda Pharmaceutical Company Limited
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 2. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, 2021 VS 2027
FIGURE 3. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 4. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 6. GLOBAL LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2027
FIGURE 7. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 8. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 10. GLOBAL LEUKEMIA THERAPEUTICS MARKET DYNAMICS
FIGURE 11. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 12. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2027
FIGURE 14. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ACUTE LYMPHOCYTIC LEUKEMIA, 2018-2027 (USD BILLION)
FIGURE 15. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2018-2027 (USD BILLION)
FIGURE 16. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, 2018-2027 (USD BILLION)
FIGURE 17. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2027 (USD BILLION)
FIGURE 18. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2021 VS 2027 (%)
FIGURE 19. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 20. GLOBAL LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY TREATMENT TYPE, 2027
FIGURE 21. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2027 (USD BILLION)
FIGURE 22. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED DRUGS & IMMUNOTHERAPY, 2018-2027 (USD BILLION)
FIGURE 23. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2021 VS 2027 (%)
FIGURE 24. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 25. GLOBAL LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY MOLECULE TYPE, 2027
FIGURE 26. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2027 (USD BILLION)
FIGURE 27. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2027 (USD BILLION)
FIGURE 28. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2021 VS 2027 (%)
FIGURE 29. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2021 VS 2027 (USD BILLION)
FIGURE 30. GLOBAL LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY MODE OF ADMINISTRATION, 2027
FIGURE 31. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MODE, 2018-2027 (USD BILLION)
FIGURE 32. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL MODE, 2018-2027 (USD BILLION)
FIGURE 33. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2021 VS 2027 (%)
FIGURE 34. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2021 VS 2027 (USD BILLION)
FIGURE 35. GLOBAL LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY GENDER, 2027
FIGURE 36. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY FEMALE, 2018-2027 (USD BILLION)
FIGURE 37. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MALE, 2018-2027 (USD BILLION)
FIGURE 38. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 39. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 40. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 41. AMERICAS LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 42. ARGENTINA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 43. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 44. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 45. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 46. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 47. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 48. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 49. UNITED STATES LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 50. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 51. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 52. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 53. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 54. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 55. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 56. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 57. INDONESIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 58. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 59. MALAYSIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 60. PHILIPPINES LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 61. SINGAPORE LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 62. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 63. TAIWAN LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 64. THAILAND LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 65. VIETNAM LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 66. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 67. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 68. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 69. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 70. DENMARK LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 71. EGYPT LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 72. FINLAND LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 73. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 74. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 75. ISRAEL LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 76. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 77. NETHERLANDS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 78. NIGERIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 79. NORWAY LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 80. POLAND LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 81. QATAR LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 82. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 83. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 84. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 85. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 86. SWEDEN LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 87. SWITZERLAND LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 88. TURKEY LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 89. UNITED ARAB EMIRATES LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 90. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 91. GLOBAL LEUKEMIA THERAPEUTICS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 92. GLOBAL LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 93. GLOBAL LEUKEMIA THERAPEUTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021